4Sc AG develops drugs against cancer. See these slides from February 2022. Their prime candidate drug is Resminostat, a small molecule that can be administered orally. It already has orphan status for use against mycosis fungoides and sezary syndrome, which are both
4Sc AG: promising biotech net-net, also…
4Sc AG develops drugs against cancer. See these slides from February 2022. Their prime candidate drug is Resminostat, a small molecule that can be administered orally. It already has orphan status for use against mycosis fungoides and sezary syndrome, which are both
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.